News
ER+/ HER2 - ve Breast Cancer Market Insight, Epidemiology, and Market Forecast Report 2022-2036
3+ hour, 47+ min ago (379+ words) Opportunities in the ER+/HER2- breast cancer market include the growth of novel CDK4/6 inhibitors and next-generation SERDs, offering advanced treatment options. Strong R&D from players like Astra Zeneca and Roche, coupled with the rising incidence, presents significant potential. Enhanced market…...
Does Pediatrix's Earnings-Accretive Tennessee Deal Reshape the Bull Case for Maternal-Fetal Care Specialist MD?
1+ week, 1+ day ago (274+ words) Pediatrix Medical Group, Inc. recently expanded its presence in Middle Tennessee by acquiring Tennessee Maternal-Fetal Medicine in a cash deal, rebranding the five-location practice as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix banner and adding four board-certified physicians plus…...
San Antonio Breast Cancer Symposium" fuels $39. 6 million impact and advances in cancer care
1+ week, 5+ day ago (497+ words) SAN ANTONIO, March 31, 2026 /PRNewswire/ -- The San Antonio Breast Cancer Symposium" drew more than 11, 000 attendees to downtown San Antonio and generated nearly $40 million in economic impact, according to a new report from Visit San Antonio. Held each December at the Henry…...
Pediatrix Ties Up to Provide Better Maternal Care in Tennessee
2+ week, 2+ day ago (472+ words) Pediatrix Medical Group, Inc. MD recently teamed up with Tennessee Maternal-Fetal Medicine, a specialist group focused on high-risk pregnancies and serving patients across five locations in the Greater Nashville area. The move is aimed at expanding the maternal health services…...
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
3+ week, 3+ day ago (544+ words) Novartis struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology pipeline with a new treatment approach. The Swiss drugmaker has turned to dealmaking to replenish its drug…...
Novartis agrees to acquire a pan-mutant-selective PI3 K" inhibitor, strengthening its breast cancer pipeline
3+ week, 3+ day ago (202+ words) The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3 K" mutations in breast cancer while sparing wild-type PI3 K", thus reducing unwanted side effects and improving tolerability Addresses a well'defined patient population with significant unmet need…...
$1 M Donation by Lume Deodorant Founder Marks the Largest Single Gift to Fund Lobular Breast Cancer Research
3+ week, 4+ day ago (130+ words) Boston, MA, USA, March 19, 2026 (GLOBE NEWSWIRE) -- Lobular Breast Cancer Alliance Launches "Match the Million" Challenge to Double Historic Gift This Women's History Month, Lume Deodorant founder and lobular breast cancer survivor, Dr. Shannon Klingman, has made a historic $1 million gift…...
New National Research Finds Americans Ready to Act on Maternal Health
3+ week, 3+ day ago (293+ words) Heartland Forward Calls It a National Priority BENTONVILLE, Ark. , March 19, 2026 /PRNewswire/ -- Americans are united on maternal health'and the path forward is clear. New national research commissioned by Heartland Forward reveals a massive, bipartisan groundswell of support for maternal health reform…...
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference
4+ week, 2+ day ago (18+ words) Yahoo Finance Oops, something went wrong...
UNICOS Launches V-Flash Eyeliner Stamp, Bringing One-Press Winged Liner to Busy Beauty Routines
1+ mon, 2+ week ago (482+ words) NEW YORK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- UNICOS Beauty has launched the V-Flash Eyeliner Stamp, a new makeup tool designed to simplify one of beauty's most time-consuming steps: winged eyeliner. Featuring a patented pressing mechanism, the product delivers a clean, symmetrical wing…...